Tag: GlobeNewswire

• Q3 revenue increased 40% year-over-year to a record $252 million, driven by robust marketplace growth.
• Q3 marketplace revenue increased 43% year-over-year, driven by expanding networks of buyers and suppliers and increasing wallet share.
• Q3 gross profit increased 37% year-over-year to a record $98.7 million, driven by strong marketplace growth. Record Q3 marketplace gross margin of 36.0%, an increase of 30 bps year-over-year.
• Q3 Adjusted EBITDA improved $15.3 million year-over-year to Adjusted EBITDA of $21.4 million, driven by strong marketplace gross profit growth and significant operating expense leverage.
• Strong operating results were driven by consistent execution across growth initiatives: establishing Xometry as the infrastructure for custom manufacturing, improving AI-native marketplace experiences, expanding buyer and supplier networks, deepening enterprise engagement and leveraging services opportunities.

NORTH BETHESDA, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) — Xometry, Inc. (NASDAQ: XMTR), the global AI-native marketplace connecting buyers and suppliers of custom manufacturing, today announced its financial results for the third quarter ended September 30, 2026.

“Our key growth initiatives drove record results in the third quarter, with marketplace growth of 43% year-over-year, as we surpassed the $1 billion revenue run rate. We further improved our marketplace experience and continue to deepen enterprise engagement, driving record net buyer additions and increasing wallet share in larger accounts,” said Sanjeev Singh Sahni, CEO at Xometry. “We continue to strengthen Xometry’s position as the infrastructure layer for custom manufacturing, enabling us to rapidly scale online adoption and accelerate market share gains.”

“Our record-setting Q3 performance demonstrates the compounding growth and operational efficiency of our marketplace, delivering both strong revenue expansion and margin improvement,” said James Miln, CFO at Xometry. “Revenue growth remained robust at the 40% level for the second quarter in a row, alongside record marketplace gross margin of 36.0%. This durable top line growth was paired with yet another quarter of improved Adjusted EBITDA profit margin, up 510 basis points year-over-year to 8.5%.”                                                                                                    

Third Quarter 2026 Financial Highlights

• Total revenue for the third quarter of 2026 was $252 million, an increase of 40% year-over-year.
• Total gross profit for the third quarter of 2026 was $98.7 million, an increase of 37% year-over-year. Total gross margin for the third quarter of 2026 was 39.1%.
• Marketplace revenue for the third quarter of 2026 was $238 million, an increase of 43% year-over-year.
• Marketplace Active Buyers increased 20% from 78,282 as of September 30, 2025 to 93,812 as of September 30, 2026, with record net buyer additions of 4,255 in the third quarter of 2026.
• Marketplace Accounts with Last Twelve-Months Spend of at least $50,000 increased 26% from 1,724 as of September 30, 2025 to 2,172 as of September 30, 2026.
• Services revenue for the third quarter of 2026 was $14.4 million, up 2% year-over-year. 
• Net income attributable to common stockholders for the third quarter of 2026 was $1.9 million, as compared to net loss attributable to common stockholders of $11.6 million in the third quarter of 2025.
• Adjusted EBITDA for the third quarter of 2026 was $21.4 million, reflecting an improvement of $15.3 million year-over-year.
• Non-GAAP net income for the third quarter of 2026 was $18.6 million, as compared to a Non-GAAP net income of $2.1 million in the third quarter of 2025. 
• Cash, cash equivalents and marketable securities were $505 million as of September 30, 2026.

Third Quarter 2026 Business Highlights  

• Xometry unveiled its next-gen Workcenter experience for manufacturing partners, building on the AI sourcing models introduced in July. The redesigned homepage unifies job discovery, performance scores and payout visibility, and the enhanced Job Board offers filters and an on-screen 3D viewer and drawing review.
• Xometry expanded its partnership with TradeCentric, adding Purchase Order Automation and Invoice Automation to the PunchOut capability already available between its marketplace and customers’ eProcurement systems. The integration connects with over 220 eProcurement solutions, including Coupa, SAP Ariba and Microsoft Dynamics, and is available now to U.S. customers, with international expansion planned.
• Xometry Foundation announced a partnership with MxD, the nation’s Digital Manufacturing and Cybersecurity Institute, aimed at making cybersecurity compliance, including CMMC Level 2, more affordable for small and mid-sized manufacturers. The grant program is part of Xometry’s broader commitment to strengthening the U.S. aerospace and defense industrial base. 
• Xometry released data showing job growth among its Texas supplier partners tracking at nearly twice the rate of its national partner network in 2026, driven by demand for certified manufacturing capabilities.

Financial Summary
(In thousands, except per share amounts)
(Unaudited)

		For the Three Months Ended September 30,											For the Nine Months Ended September 30,
		2026				2025				% Change			2026				2025				% Change
Consolidated
Revenue		$	252,439			$	180,715			40	%		$	686,857			$	494,234			39	%
Gross profit			98,680				72,029			37	%			264,321				193,536			37	%
Net income (loss) attributable to common stockholders			1,935				(11,597	)		117	%			(8,645	)			(53,109	)		84	%
EPS, basic and diluted, of Class A and Class B common stock			0.03				(0.23	)		113	%			(0.16	)			(1.05	)		85	%
Adjusted EBITDA(1)			21,423				6,142			249	%			46,050				10,146			354	%
Non-GAAP net income(1)			18,561				2,103			783	%			35,362				656			5,291	%
Non-GAAP EPS, basic(1), of Class A and Class B common stock			0.32				0.04			700	%			0.65				0.01			6,400	%
Non-GAAP EPS, diluted(1), of Class A and Class B common stock			0.28				0.04			600	%			0.57				0.01			5,600	%
Marketplace
Revenue		$	238,004			$	166,592			43	%		$	644,691			$	451,168			43	%
Cost of revenue			152,306				107,086			42	%			417,787				295,891			41	%
Gross Profit		$	85,698			$	59,506			44	%		$	226,904			$	155,277			46	%
Gross Margin			36.0	%			35.7	%		0.3	%			35.2	%			34.4	%		0.8	%
Services
Revenue		$	14,435			$	14,123			2	%		$	42,166			$	43,066			(2	)%
Cost of revenue			1,453				1,600			(9	)%			4,749				4,807			(1	)%
Gross Profit		$	12,982			$	12,523			4	%		$	37,417			$	38,259			(2	)%
Gross Margin			89.9	%			88.7	%		1.2	%			88.7	%			88.8	%		(0.1	)%

(1) These non-GAAP financial measures, and the reasons why we believe these non-GAAP financial measures are useful, are described below and reconciled to their most directly comparable GAAP measures in the accompanying tables.

Key Operating Metrics⁽²⁾:

		As of September 30,
		2026				2025				% Change
Active Buyers(3)			93,812				78,282				20	%
Percentage of Revenue from Existing Accounts(3)			98	%			98	%
Accounts with Last Twelve-Months Spend of at Least $50,000(3)			2,172				1,724				26	%

(2) These key operating metrics are for Marketplace. See “Key Terms for our Key Metrics and Non-GAAP Financial Measures” below for definitions of these metrics.
(3) Amounts shown for Active Buyers and Accounts with Last Twelve-Months Spend of at Least $50,000 are as of September 30, 2026 and 2025, and Percentage of Revenue from Existing Accounts is presented for the quarters ended September 30, 2026 and 2025.       

Financial Guidance and Outlook:

		Q4 2026
		(in millions)
		Low				High
Revenue		$	254			$	256
Adjusted EBITDA		$	22.0			$	22.5

• For Q4 2026, we expect revenue of $254-$256 million, representing 32-33% growth year-over-year driven by approximately 35-36% marketplace growth.
• For Q4 2026, we expect Adjusted EBITDA of $22-$22.5 million, an improvement from Adjusted EBITDA of $8.4 million in Q4 2025.
• For Full Year 2026, we are raising our revenue growth outlook from previous guidance of 33-34% to at least 37% driven by approximately 41% marketplace growth.
• For Full Year 2026, we expect Adjusted EBITDA of $68-$68.5 million, an improvement from an Adjusted EBITDA of $18.5 million in Full Year 2025.

Xometry’s fourth quarter and full year 2026 financial outlook is based on a number of assumptions that are subject to change and may be outside of its control. If actual results vary from these assumptions, Xometry’s expectations may change. There can be no assurance that Xometry will achieve these results.

Reconciliation of Adjusted EBITDA on a forward-looking basis to net loss, the most directly comparable GAAP measure, is not available without unreasonable efforts due to the high variability and complexity and low visibility with respect to certain charges excluded from this non-GAAP measure, including interest and dividend income, (provision) benefit for income taxes, charitable contributions of common stock and impairment of assets. Xometry expects the variability of these items could have a significant, and potentially unpredictable, impact on its future GAAP financial results.  

Use of Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are prepared and presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”), Xometry, Inc. (“Xometry”, the “Company”, “we” or “our”) uses Adjusted EBITDA, non-GAAP net income and non-GAAP Earnings Per Share, basic and diluted, which are considered non-GAAP financial measures, as described below. These non-GAAP financial measures are presented to enhance the user’s overall understanding of Xometry’s financial performance and should not be considered a substitute for, nor superior to, the financial information prepared and presented in accordance with GAAP. The non-GAAP financial measures presented in this release, together with the GAAP financial results, are the primary measures used by the Company’s management and board of directors to understand and evaluate the Company’s financial performance and operating trends, including period-to-period comparisons, because they exclude certain expenses and gains that management believes are not indicative of the Company’s core operating results. Management also uses these measures to prepare and update the Company’s short and long term financial and operational plans, to evaluate investment decisions, and in its discussions with investors, commercial bankers, equity research analysts and other users of the Company’s financial statements. Accordingly, the Company believes that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating the Company’s operating results in the same manner as the Company’s management and in comparing operating results across periods and to those of Xometry’s peer companies. In addition, from time to time we may present adjusted information (for example, revenue growth) to exclude the impact of certain gains, losses or other changes that affect period-to-period comparability of our operating performance.

The use of non-GAAP financial measures has certain limitations because they do not reflect all items of income and expense, or cash flows, that affect the Company’s financial performance and operations. Additionally, non-GAAP financial measures do not have standardized meanings, and therefore other companies, including peer companies, may use the same or similarly named measures but exclude or include different items or use different computations. Management compensates for these limitations by reconciling these non-GAAP financial measures to their most comparable GAAP financial measures in the tables captioned “Reconciliations of Non-GAAP Financial Measures” included at the end of this release. Investors and others are encouraged to review the Company’s financial information in its entirety and not rely on a single financial measure.

Change in Non-GAAP Financial Measure

Effective January 1, 2026, we revised our definition of Non-GAAP Net Income to exclude depreciation expense which had previously been included as an adjustment. Management believes this revised definition provides a more representative view of our core operating performance. All prior-period amounts have been recast to conform to this new definition.

Key Terms for our Key Metrics and Non-GAAP Financial Measures

Marketplace revenue: includes the sale of parts and assemblies on our platform.

Services revenue: includes the sales of marketing and advertising services and, to a lesser extent, financial service products and SaaS-based solutions.

Active Buyers: The Company defines “buyers” as individuals who have placed an order to purchase on-demand parts or assemblies on our marketplace. The Company defines Active Buyers as the number of buyers who have made at least one purchase on our marketplace during the last twelve months.

Active Suppliers: The Company defines “suppliers” as individuals or businesses that have been approved by us to either manufacture a product on our platform for a buyer or have utilized our supplier services, including our digital marketing services, data services, financial services or tools and materials. The Company defines Active Suppliers as suppliers that have used our platform at least once during the last twelve months to manufacture a product.

Percentage of Revenue from Existing Accounts: The Company defines an “account” as an individual entity, such as a sole proprietor with a single buyer or corporate entities with multiple buyers, having purchased at least one part on our marketplace. The Company defines an existing account as an account where at least one buyer has made a purchase on our marketplace.

Accounts with Last Twelve-Month Spend of at Least $50,000: The Company defines Accounts with Last Twelve-Month Spend of at Least $50,000 as an account that has spent at least $50,000 on our marketplace in the most recent twelve-month period.

Adjusted earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA): The Company defines Adjusted EBITDA as net income (loss), adjusted for interest expense, interest and dividend income and other expenses, depreciation and amortization, amortization of lease intangible, provision for (benefit from) income taxes, stock-based compensation, payroll tax expense related to stock-based compensation, charitable contributions of common stock, income from unconsolidated joint venture, impairment of assets, restructuring charges and acquisition and other adjustments not reflective of the Company’s ongoing business, such as adjustments related to purchase accounting, the revaluation of contingent consideration, transaction costs and executive severance.

Non-GAAP net income: The Company defines non-GAAP net income as net loss adjusted for stock-based compensation, payroll tax expense related to stock-based compensation, amortization of lease intangible, amortization of deferred costs on convertible notes, charitable contributions of common stock, lease termination, impairment of assets, restructuring charges, loss on debt extinguishment, amortization of acquired intangible assets & patents, other amortization and acquisition and other adjustments not reflective of the Company’s ongoing business, such as adjustments related to purchase accounting, the revaluation of contingent consideration, transaction costs and executive severance.

Non-GAAP Earnings Per Share, basic and diluted (Non-GAAP EPS, basic and diluted): The Company calculates non-GAAP earnings per share, basic and diluted as non-GAAP net income divided by the weighted average number of basic or dilutive shares of common stock outstanding.

Management believes that the exclusion of certain expenses and gains in calculating adjusted EBITDA, non-GAAP net income and non-GAAP EPS, basic and diluted, provides a useful measure for period-to-period comparisons of the Company’s underlying core revenue and operating costs that is focused more closely on the current costs necessary to operate the Company’s businesses and reflects its ongoing business in a manner that allows for meaningful analysis of trends. Management also believes that excluding certain non-cash charges can be useful because the amount of such expenses is the result of long-term investment decisions made in previous periods rather than day-to-day operating decisions.

About Xometry
Xometry’s (NASDAQ: XMTR) AI-native marketplace, popular Thomasnet® industrial sourcing platform and suite of cloud-based services are rapidly digitizing the manufacturing industry. Xometry provides manufacturers the critical resources they need to grow their business and streamlines the procurement process for buyers through real-time pricing and lead time data. Learn more at xometry.com and xometry.eu.

Conference Call and Webcast Information
The Company will host a conference call and webcast to discuss the results at 8:30 a.m. ET (5:30 a.m. PT) on November 3, 2026. In addition to its press release announcing its third quarter 2026 financial results, Xometry will release an earnings presentation, which will be available on its investor website at investors.xometry.com.

Xometry, Inc. Third Quarter 2026 Earnings Presentation and Conference Call

• Tuesday, November 3, 2026
• 8:30 a.m. Eastern / 5:30 a.m. Pacific
• To access the webcast use the following link: https://register-conf.media-server.com/register
• You may also visit the Xometry Investor Relations Homepage at investors.xometry.com to listen to a live webcast of the call

Cautionary Information Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “would,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to, our beliefs regarding our financial position and operating performance, including our outlook and guidance for the fourth quarter of 2026 and the full year 2026; our expectations regarding our growth; and statements regarding our strategies, initiatives, products and platform capabilities. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks and uncertainties related to: competition, managing our growth, financial performance, our ability to forecast our performance due to our limited operating history, investments in new products or offerings, our ability to attract buyers and sellers to our marketplace, legal proceedings and regulatory matters and developments, any future changes to our business or our financial or operating model, our brand and reputation, and the impact of fluctuations in general macroeconomic conditions, such as fluctuations in inflation and rising interest rates. The forward-looking statements contained in this press release are also subject to other risks and uncertainties that could cause actual results to differ from the results predicted, including those more fully described in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2025, our Quarterly Reports on Form 10-Q, and other filings and reports that we may file from time to time with the SEC. All forward-looking statements in this press release are based on information available to Xometry and assumptions and beliefs as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law. 

Investor Contact:	Media Contact:
Shawn Milne VP Investor Relations 240-335-8132 shawn.milne@xometry.com	Lauran Cacciatori VP Communications 773-610-0806 lauran.cacciatori@xometry.com

Xometry, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
(Unaudited)

		September 30,				December 31,
		2026				2025
Assets
Current assets:
Cash and cash equivalents		$	18,132			$	14,996
Marketable securities			486,850				204,145
Accounts receivable, less allowance for credit losses of $9.1 million and $8.0 million as of September 30, 2026 and December 31, 2025, respectively			152,151				97,370
Inventory			3,767				3,917
Prepaid expenses			6,216				7,262
Other current assets			14,441				6,954
Total current assets			681,557				334,644
Software development and property and equipment, net			91,788				60,631
Operating lease right-of-use assets			13,142				11,132
Investment in unconsolidated joint venture			4,157				4,069
Intangible assets, net			28,008				28,563
Goodwill			268,051				263,801
Other assets			913				880
Total assets		$	1,087,616			$	703,720
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued cost of revenue		$	68,870			$	44,612
Other accrued expenses			41,769				31,669
Contract liabilities			17,667				10,319
Income taxes payable			286				269
Convertible notes, current portion			84,816				—
Operating lease liabilities, current portion			3,012				2,067
Total current liabilities			216,420				88,936
Convertible notes, net of current portion			243,607				327,514
Operating lease liabilities, net of current portion			11,198				9,841
Deferred income taxes			123				145
Other liabilities			1,349				547
Total liabilities			472,697				426,983
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.000001 par value. Authorized; 50,000,000 shares; zero shares issued and outstanding as of September 30, 2026 and December 31, 2025			—				—
Class A common stock, $0.000001 par value. Authorized; 750,000,000 shares; 55,905,317 shares and 49,842,220 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively			—				—
Class B common stock, $0.000001 par value. Authorized; 5,000,000 shares; 1,475,311 shares issued and outstanding as of September 30, 2026 and December 31, 2025			—				—
Additional paid-in capital			1,058,186				710,925
Treasury stock, at cost, 220,994 shares as of September 30, 2026 and December 31, 2025			(8,080	)			(8,080	)
Accumulated other comprehensive income			4,331				4,772
Accumulated deficit			(440,661	)			(432,016	)
Total stockholders’ equity			613,776				275,601
Noncontrolling interest			1,143				1,136
Total equity			614,919				276,737
Total liabilities and stockholders’ equity		$	1,087,616			$	703,720

Xometry, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(In thousands, except share and per share amounts)
(Unaudited)

		Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Revenue		$	252,439			$	180,715			$	686,857			$	494,234
Cost of revenue			153,759				108,686				422,536				300,698
Gross profit			98,680				72,029				264,321				193,536
Operating expenses:
Sales and marketing			35,571				32,649				101,124				88,866
Operations and support			23,264				18,403				64,332				53,225
Product development			16,102				12,524				40,510				34,703
General and administrative			23,686				19,463				69,063				53,433
Impairment of assets			—				49				—				49
Total operating expenses			98,623				83,088				275,029				230,276
Income (loss) from operations			57				(11,059	)			(10,708	)			(36,740	)
Other (expenses) income
Interest expense			(1,258	)			(1,278	)			(3,774	)			(3,648	)
Interest and dividend income			4,440				2,139				8,822				6,591
Other expenses			(787	)			(1,636	)			(2,260	)			(19,882	)
Income from unconsolidated joint venture			187				220				588				544
Total other income (expenses)			2,582				(555	)			3,376				(16,395	)
Income (loss) before income taxes			2,639				(11,614	)			(7,332	)			(53,135	)
(Provision) benefit for income taxes			(704	)			17				(1,306	)			25
Net income (loss)			1,935				(11,597	)			(8,638	)			(53,110	)
Net income (loss) attributable to noncontrolling interest			—				—				7				(1	)
Net income (loss) attributable to common stockholders		$	1,935			$	(11,597	)		$	(8,645	)		$	(53,109	)
Net income (loss) per share of Class A and Class B common stock:
Basic		$	0.03			$	(0.23	)		$	(0.16	)		$	(1.05	)
Diluted		$	0.03			$	(0.23	)		$	(0.16	)		$	(1.05	)
Weighted average shares outstanding:
Basic			57,333,901				50,920,588				54,508,819				50,653,997
Diluted			60,462,719				50,920,588				54,508,819				50,653,997
Net income (loss)		$	1,935			$	(11,597	)		$	(8,638	)		$	(53,110	)
Comprehensive income (loss):
Foreign currency translation			119				180				(441	)			4,766
Total other comprehensive income (loss)			119				180				(441	)			4,766
Comprehensive income (loss)			2,054				(11,417	)			(9,079	)			(48,344	)
Comprehensive (loss) income attributable to noncontrolling interest			(10	)			7				7				(17	)
Total comprehensive income (loss) attributable to common stockholders		$	2,064			$	(11,424	)		$	(9,086	)		$	(48,327	)

Xometry, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)

		Nine Months Ended September 30,
		2026				2025
Cash flows from operating activities:
Net loss		$	(8,638	)		$	(53,110	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			16,952				13,741
Impairment of assets			—				49
Reduction in carrying amount of right-of-use asset			1,771				3,350
Lease termination			—				(14	)
Stock-based compensation			30,961				25,985
Income from unconsolidated joint venture			(88	)			(144	)
Donation of common stock			4,404				2,080
Loss on debt extinguishment			—				16,430
Amortization of deferred costs on convertible notes			1,712				1,527
Deferred tax benefit			(22	)			(44	)
Changes in other assets and liabilities:
Accounts receivable, net			(55,096	)			(23,370	)
Inventory			79				(192	)
Prepaid expenses			1,039				(904	)
Other assets			(7,468	)			(1,233	)
Accounts payable and accrued cost of revenue			24,009				10,728
Other accrued expenses			9,920				9,100
Contract liabilities			7,395				3,170
Lease liabilities			(1,482	)			(5,202	)
Other liabilities			(54	)			(24	)
Income taxes payable			16				(249	)
Net cash provided by operating activities			25,410				1,674
Cash flows from investing activities:
Purchases of marketable securities			(341,705	)			(6,571	)
Proceeds from sale of marketable securities			59,000				20,500
Capitalization of software development and purchases of property and equipment			(38,905	)			(19,911	)
Cash paid for business combination			(4,599	)			—
Net cash used in investing activities			(326,209	)			(5,982	)
Cash flows from financing activities:
Proceeds from issuance of convertible notes			—				250,000
Costs incurred in connection with issuance of convertible notes			—				(8,650	)
Payments for repurchase of convertible notes			—				(215,992	)
Purchase of capped calls			—				(17,475	)
Purchase of treasury stock			—				(8,080	)
Proceeds from stock options exercised			6,349				2,703
Proceeds from issuance of common stock, net of underwriters’ discount			248,400				—
Payment of costs related to issuance of common stock			(776	)			—
Proceeds from issuance of common stock under Siemens agreement			50,000				—
Net cash provided by financing activities			303,973				2,506
Effect of foreign currency translation on cash and cash equivalents			(38	)			415
Net increase (decrease) in cash and cash equivalents			3,136				(1,387	)
Cash and cash equivalents at beginning of the period			14,996				22,232
Cash and cash equivalents at end of the period		$	18,132			$	20,845
Supplemental cash flow information:
Cash paid for interest		$	1,796			$	2,600
Cash paid for income taxes			1,234				—
Non-cash investing and financing activities:
Stock-based compensation included in capitalized software development costs			7,117				—
Non-cash consideration in connection with business combination			2,099				625
Non-cash purchase of property and equipment			108				74
Conversion of 2027 convertible notes to common stock			805				—

Xometry, Inc. and Subsidiaries
Reconciliations of Non-GAAP Financial Measures
(In thousands, except share and per share amounts)
(Unaudited)

		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2026				2025				2026				2025
Adjusted EBITDA:
Net income (loss)		$	1,935			$	(11,597	)		$	(8,638	)		$	(53,110	)
Add (deduct):
Interest expense, interest and dividend income and other expenses			(2,395	)			775				(2,788	)			16,939
Depreciation and amortization(1)			6,185				5,000				16,952				13,741
Amortization of lease intangible			—				180				—				540
Provision (benefit) from income taxes			704				(17	)			1,306				(25	)
Stock-based compensation(2)			11,288				10,748				30,961				25,985
Payroll tax expense related to stock-based compensation			728				366				2,792				2,100
Acquisition and other(3)			28				—				309				927
Charitable contribution of common stock			1,767				950				4,404				2,080
Income from unconsolidated joint venture			(187	)			(220	)			(588	)			(544	)
Impairment of assets			—				49				—				49
Restructuring charges(4)			1,370				(92	)			1,340				1,464
Adjusted EBITDA		$	21,423			$	6,142			$	46,050			$	10,146

		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2026				2025				2026				2025
Non-GAAP Net Income:
Net income (loss)		$	1,935			$	(11,597	)		$	(8,638	)		$	(53,110	)
Add (deduct):
Stock-based compensation(2)			11,288				10,748				30,961				25,985
Payroll tax expense related to stock-based compensation			728				366				2,792				2,100
Amortization of lease intangible			—				180				—				540
Amortization of deferred costs on convertible notes			571				590				1,712				1,527
Acquisition and other(3)			28				—				310				926
Charitable contribution of common stock			1,767				950				4,404				2,080
Lease termination			—				16				—				(14	)
Impairment of assets			—				49				—				49
Restructuring charges(4)			1,370				(92	)			1,340				1,464
Loss on debt extinguishment			—				—				—				16,430
Amortization of acquired intangible assets & patents(5)			874				804				2,481				2,411
Other amortization(5)			—				89				—				268
Non-GAAP Net Income		$	18,561			$	2,103			$	35,362			$	656
Adjustments to numerator		$	540			$	—			$	1,619			$	—
Weighted-average number of shares outstanding used to compute Non-GAAP Net Income (Loss) per share, basic and diluted, of Class A and Class B common stock			57,333,901				50,920,588				54,508,819				50,653,997
Non-GAAP effect of potentially dilutive Class A common stock			9,969,202				3,115,487				9,902,171				2,608,839
Non-GAAP weighted-average shares used to compute Non-GAAP Net Income (Loss) per share, diluted			67,303,103				54,036,075				64,410,990				53,262,836
EPS, basic and diluted, of Class A and Class B common stock		$	0.03			$	(0.23	)		$	(0.16	)		$	(1.05	)
Non-GAAP EPS basic, of Class A and Class B common stock		$	0.32			$	0.04			$	0.65			$	0.01
Non-GAAP EPS diluted, of Class A and Class B common stock		$	0.28			$	0.04			$	0.57			$	0.01

(1) Represents depreciation expense of the Company’s long-lived tangible assets and amortization expense of its finite-lived intangible assets, as included in the Company’s GAAP results of operations.
(2) Represents the non-cash expense related to stock-based awards granted to employees, as included in the Company’s GAAP results of operations.
(3) Includes adjustments related to purchase accounting, the revaluation of contingent consideration, transaction costs and executive severance.
(4) Costs associated with the 2026 and 2025 reductions in workforce.
(5) In the first quarter of 2026, we changed the definition of Non-GAAP Net Income to exclude depreciation expense. Prior period amounts were recast to conform to the new definition.

Xometry, Inc. and Subsidiaries
Reconciliation of GAAP EPS to Non-GAAP EPS
(Unaudited)

		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2026				2025				2026				2025
Non-GAAP EPS:
GAAP EPS, diluted, of Class A and Class B common stock		$	0.03			$	(0.23	)		$	(0.16	)		$	(1.05	)
Non-GAAP effect of potentially dilutive Class A common stock			—				0.02				0.05				0.03
Add (deduct):
Stock-based compensation			0.17				0.20				0.48				0.49
Payroll tax expense related to stock-based compensation			0.01				0.01				0.04				0.04
Amortization of lease intangible			—				—				—				0.01
Amortization of deferred costs on convertible notes			0.01				0.01				0.03				0.03
Acquisition and other			—				—				—				0.02
Charitable contribution of common stock			0.03				0.02				0.07				0.04
Impairment of assets			—				—				—				—
Restructuring charges			0.02				—				0.02				0.03
Loss on debt extinguishment			—				—				—				0.31
Amortization of acquired intangible assets & patents			0.01				0.01				0.04				0.05
Other amortization			—				—				—				0.01
Non-GAAP EPS, diluted, of Class A and Class B common stock		$	0.28			$	0.04			$	0.57			$	0.01

Xometry, Inc. and Subsidiaries
Segment Results
(In thousands)
(Unaudited)

		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2026				2025				2026				2025
Segment Revenue:
U.S.		$	213,392			$	151,093			$	580,357			$	414,646
International			39,047				29,622				106,500				79,588
Total revenue		$	252,439			$	180,715			$	686,857			$	494,234
Segment Cost of Revenue:
U.S.		$	130,596			$	90,933			$	357,882			$	251,841
International			23,163				17,753				64,654				48,857
Total cost of revenue		$	153,759			$	108,686			$	422,536			$	300,698
Segment Adjusted EBITDA:
U.S.		$	22,020			$	10,349			$	52,769			$	20,234
International			(597	)			(4,207	)			(6,719	)			(10,088	)
Total Adjusted EBITDA		$	21,423			$	6,142			$	46,050			$	10,146

Xometry, Inc. and Subsidiaries
Supplemental Information
(In thousands)
(Unaudited)

		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2026				2025				2026				2025
Summary of Stock-based Compensation Expense and Payroll Taxes Related to Stock-Based Compensation Expense
Sales and marketing		$	2,694			$	3,170			$	7,201			$	7,809
Operations and support			2,839				3,712				8,552				9,450
Product development			1,250				2,583				4,036				6,410
General and administrative			5,233				1,649				13,964				4,416
Total stock-based compensation expense and payroll taxes related to stock-based compensation		$	12,016			$	11,114			$	33,753			$	28,085
Summary of Depreciation and Amortization Expense
Cost of revenue		$	179			$	184			$	538			$	550
Sales and marketing			805				799				2,384				2,385
Operations and support			76				46				145				129
Product development			5,060				3,723				13,353				9,860
General and administrative			65				248				532				817
Total depreciation and amortization expense		$	6,185			$	5,000			$	16,952			$	13,741
Summary of Restructuring Charges
Sales and marketing		$	190			$	(27	)		$	190			$	62
Operations and support			429				(108	)			431				718
Product development			731				11				733				510
General and administrative			20				32				(14	)			174
Total restructuring charges		$	1,370			$	(92	)		$	1,340			$	1,464

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES.

VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) — JZR Gold Inc. (TSXV: JZR) (OTCPK: JZRIF) (the “Company” or “JZR”) is pleased to announce that, on October 29, 2026, an additional 15 tonnes of gold concentrate has been delivered to Recuperadora Brasileira de Metal (“RBM”), a precious metals refining and recovery plant located in São Paulo, Brazil. This brings the total gold concentrate delivered to RBM to 26 tonnes, including the initial shipment of 11 tonnes.

JZR has contracted RBM to process the gold concentrate derived from the Vila Nova Gold Property located in the State of Amapa, Brazil. RBM has completed the setup and testing of its leaching and carbon-in-leach (CIL) circuit, which is fully operational.

Processing of all 26 tonnes of gold concentrate is underway. The Company expects to receive results confirming the quantity of gold within the next two weeks.

JZR is a party to a Joint Venture Royalty Agreement (“JVRA”) dated July 6, 2020, as amended, with ECO Mineracao Oil and Gaz Drilling and Exploration EIRELI (“ECO”), pursuant to which JZR is entitled to receive 50% of the Net Profit Interest (as defined in the JVRA) in respect of the total sale value of all gold from the tailings piles and dams, pond basin and waste dumps on the Vila Nova property.

Rob Klenk, CEO of JZR Gold, commented: “We are extremely excited to reach this point in JZR’s history. With all 26 tonnes delivered and processing underway, we are advised that ECO is on the verge of generating the first gold revenue, from which the company expects to receive its entitled royalty payment interest. This is a transformational milestone for JZR and our shareholders. We look forward to receiving results from the refining process over the next two weeks and sharing those numbers with our shareholders.”

About JZR Gold Inc.

JZR Gold Inc. is focused on working with ECO to advance the Vila Nova Gold Project in Amapá State, Brazil. The Company has assumed operatorship of the Project and is focused on establishing reliable processing operations utilizing the existing permitted processing facility and associated infrastructure.

For further information, please contact:

Robert Klenk
Chief Executive Officer
rob@jzrgold.com

Forward-Looking Information

This news release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the Company’s plans and objectives for the Vila Nova Gold Project, increasing operating hours of the processing facility, statements regarding the Company’s plans to improve efficiency, achieving consistent and sustained production, and the Company’s expectations regarding the future performance of the Project. Forward-looking statements are based on management’s current expectations and assumptions and are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such statements. Readers are cautioned not to place undue reliance on forward-looking statements. JZR Gold undertakes no obligation to update such statements except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

None of the securities of JZR have been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law, and may not be offered or sold in the United States or to, or for the account or benefit of, persons in the United States or “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act) absent registration or an exemption from such registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy in the United States nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

NEW HAVEN, Conn., Nov. 03, 2026 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD) today announced that on November 1, 2026, Invivyd granted seven newly hired non-executive employees options to purchase an aggregate of 175,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan. 

The options have a per share exercise price of $0.5817, representing the closing price of Invivyd’s common stock on October 30, 2026, the last trading date prior to the date of grant. Each option vests over four years, with 25% of the shares subject to such option vesting on the first anniversary of the employee’s start date and the remaining shares vesting in equal monthly installments thereafter, in each case, subject to the employee’s continuous service with Invivyd. The options have a 10-year term and are subject to the terms of the Invivyd, Inc. 2026 Inducement Plan. 

About Invivyd   

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.  

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release. 

Contacts: 

Media Relations 
(781) 208-0160 
media@invivyd.com 

Investor Relations 
(781) 208-1747 
investors@invivyd.com 

TORONTO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Labrador Gold Corp. (TSX.V: LAB | FNR: 2N6) (“LabGold” or the “Company”) announces that, effective today, Raymond D. Harari, a director of LabGold, has been appointed as President of the Company, and that Robert Mason has been appointed as Corporate Secretary.

“I am delighted to welcome Ray as President and Rob as Corporate Secretary of LabGold,” said Roger Moss, Chief Executive Officer of LabGold. “Since joining the Board of Directors in mid-October, Ray has already made an immense contribution to the Company, bringing a fresh perspective, tremendous energy and a wealth of capital markets experience. His impact has been immediate, and I am confident that his expanded leadership role will be instrumental as we evaluate strategic opportunities and position LabGold for its next phase of growth. Rob’s extensive experience in securities law, corporate governance and mining transactions further strengthens our team at an important time for the Company. I look forward to working closely with both Ray and Rob as we pursue our shared objective of maximizing shareholder value.”

Mr. Harari is the founder of Canalis Capital, a Panama-based merchant banking firm focused on the natural resources sector. He has extensive experience in corporate finance, capital markets and strategic transactions, having held senior executive and board positions with numerous publicly traded mineral exploration companies throughout his career.

Mr. Mason is the founder and principal of Mason Law, a Toronto-based law firm specializing in corporate and securities law, mergers and acquisitions, and mining transactions. Mr. Mason has over 25 years of experience advising publicly traded companies, institutional investors and boards of directors on corporate finance, capital markets transactions, strategic acquisitions and corporate governance matters.

To create vacancies for the appointments of Messrs. Harari and Mason, Dr. Roger Moss has resigned as President, remaining as the Company’s Chief Executive Officer and director, and Mr. Bill Johnstone has resigned as corporate secretary. The Company thanks Mr. Johnstone for his six plus years of service to LabGold.

About Labrador Gold

Labrador Gold is a Canadian-based hybrid mining and investment issuer focused on the acquisition and exploration of prospective mineral projects in Canada and on strategic investments in mining companies and assets that the Company believes have the potential to generate long-term value.

The Mariposa project covers 16,000 ha in the White Gold District and is 40 kilometres southeast of the White Gold Project and 30 kilometres east-northeast of Fuerte’s Coffee gold project. Mariposa shares many geological similarities to both the Golden Saddle (part of the White Gold Project) and Coffee gold deposits including host lithologies, mineralization style and structural control. The property occurs at the headwaters of significant placer gold producing creeks with historic placer production of 73,000 oz from Scroggie Creek (3) indicative of significant bedrock gold mineralization yet to be fully defined. Six significant gold occurrences have been delineated by over 13,000 soil samples to date, including the most advanced Skookum Main and Skookum West prospects. LabGold has the option to earn a 100% interest in the Mariposa project from Pacific Ridge Exploration Ltd.

The Watson Project, a 70:30 joint venture with Nemo Resources Inc., represents the largest landholding in the Fort Hope Greenstone Belt which is significantly underexplored compared to other greenstone belts (e.g. Red Lake and Pickle Lake) in northwestern Ontario. While the exploration focus will be on gold, the Watson project also hosts significant potential for critical minerals (e.g. antimony, nickel, copper and zinc). The proposed road to the Ring of Fire, expected to begin construction in mid-2026, runs through the Watson property and, once complete, will significantly reduce exploration and development costs.

The 100% owned Hopedale property covers much of the Archean-age Florence Lake greenstone belt, which extends over 60 kilometers. While typical of greenstone belts globally, the area has been underexplored. LabGold’s work to date has identified gold anomalies in rocks, soils, and lake sediments across a three-kilometer section of the northern portion of the belt. Five gold occurrences lie along this trend, four of which were discovered by LabGold. Additional anomalous gold values occur across approximately 40 kilometers of the southern portion of the belt. Recent exploration has also demonstrated potential for copper, nickel, and cobalt.

The 100% owned Borden Lake project near Chapleau, Ontario lies immediately southeast of Discovery Silver Corp’s Borden gold mine. Past exploration by LabGold identified two anomalous gold zones based on geochemistry and geophysics.

The Company has 286,012,288 common shares issued and outstanding and trades on the TSX Venture Exchange under the symbol LAB.

For more information, please contact:

Roger Moss, CEO and Director
Tel: 416-704-8291
Email: rmoss@labradorgold.com

Website: www.labradorgold.com
X: @LabGoldCorp

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. Forward-looking information is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including management’s perceptions of historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. Any such forward-looking information is based on information currently available to LabGold and is based on assumptions and analyses made in light of LabGold’s experience and perception of historical trends and current conditions. While the Company considers these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. Readers are cautioned that actual results may vary from the forward-looking information, and undue reliance should not be placed on such forward-looking information.

By their nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. Additional risk factors can also be found in LabGold’s financial statements and management’s discussion and analysis, which are available under LabGold’s profile on SEDAR+ at www.sedarplus.ca.

Unless otherwise indicated, the forward-looking statements in this news release are based on the Company’s expectations at the date of this news release. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. LabGold undertakes no obligation to update or revise such forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise, except as required by applicable law.

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will participate in three upcoming investor conferences:

• 3^rd Annual Guggenheim Healthcare Innovation Conference; fireside chat on Tuesday, November 10, 2026, at 2:00 p.m. ET
• 2026 Jefferies Global Healthcare Conference in London; presentation on Tuesday, November 17, 2026, at 10:30 a.m. ET / 3:30 p.m. GMT
• 9^th Annual Evercore Healthcare Conference; fireside chat on Tuesday, December 1, 2026, at 9:35 a.m. ET

Live webcasts of the events will be available in the Investors section of the Maze Therapeutics website at www.mazetx.com and archived for 60 days following the presentations.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor in Phase 2 development with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow Maze on LinkedIn and X.

IR/Corporate Contact:
Argot Partners
maze@argotpartners.com

Media Contact:
Amanda Lazaro, 1AB Media
Amanda@1ABMedia.com

Combining comprehensive LiDAR sensing, agentic AI-powered analytics, and technology collaborations to advance smart cities, critical infrastructure and safe spaces.

SUNNYVALE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — Seyond, a global provider of high-performance LiDAR solutions, is expanding its smart city and smart spaces solutions through advanced 3D sensing and technology collaborations. By connecting spatial data with agentic AI-powered analytics and computing platforms, Seyond helps organizations improve safety, transportation, and infrastructure operations.

Growing Demand for Smart Cities and Intelligent Infrastructure

Smart cities are becoming an operational priority as organizations seek real-time intelligence to improve safety, transportation and operational efficiency. According to LP Information, the global smart-city LiDAR market was valued at approximately $358 million in 2025, with a projected compound annual growth rate of 18.7%, suggesting a market of approximately $425 million in 2026.

Demand for spatial intelligence now extends beyond roadways to airports, stadiums, utilities, data centers, and other critical infrastructures. These applications create opportunities to better understand movement, optimize space utilization, and improve operations.

Based on industry research and internal assumptions, Seyond estimates an illustrative annual serviceable addressable market of $1.3 billion to $2.0 billion in 2026 for expanded stationary LiDAR applications outside China. This sensor-focused estimate represents potential market opportunity, not projected company revenue.

Seyond: Enabling Spatial Intelligence Across Smart Environments

Seyond’s comprehensive LiDAR portfolio, spanning ultra-long-range to short-range sensing, supports applications from transportation infrastructure to localized indoor and outdoor environments. Its technology generates high-resolution 3D spatial data to measure vehicle movement, pedestrian flows, and environmental activity without relying on identifiable photographic imagery, providing a privacy-conscious foundation for spatial analytics.

These capabilities support continuous spatial awareness across intersections, transportation hubs, commercial facilities, and public gathering spaces. Combined with AI-powered analytics and computing platforms, Seyond’s sensing technology helps organizations translate physical-world data into actionable insights, enabling more responsive infrastructure and better-informed operational decisions.

Expanding Technology Collaborations to Deliver Complete Operational Twin Solutions

Delivering practical smart city solutions increasingly requires collaboration across sensing, computing, AI, and software. One example is the digital operational twins, dynamic digital representation of a physical environment that reflects activity and movement in real time, helping operators understand changing conditions and make informed decisions.

At Smart City Expo World Congress 2026, November 3–5 in Barcelona, Seyond will participate as an exhibition partner at the Dell Technologies booth, showcasing a live LiDAR-powered operational twin.

By combining Seyond’s sensing capabilities with technologies from Dell and NVIDIA, the demonstration will illustrate how integrated solutions can support pedestrian-flow analysis, space utilization, and real-time operational awareness. The solution will feature a Dell Technologies system powered by the NVIDIA DGX Spark, which combines a 20-core Arm Grace CPU with an NVIDIA Blackwell GPU. Fused data from LiDAR, video, and other sensors feeds a live operational twin, giving operators a unified view of activity across the environment. The solution integrates vision AI agents built with NVIDIA Metropolis Blueprint for video search and summarization (VSS) and NVIDIA Cosmos to enhance scene understanding and support informed operational decisions.

Seyond is also collaborating with AMSYS to advance integrated spatial intelligence solutions for large-scale venues and public environments. Combining Seyond’s LiDAR sensing with the AMSYS Fusion Core Perception Platform, these solutions are designed to translate anonymous movement and occupancy data into actionable operational insights.

In a stadium or major event venue, for example, this approach could help operators monitor crowd density, analyze queues, and identify congestion across entrances and gathering areas. These insights could support better decisions about staffing, crowd movement, and resource allocation while maintaining a privacy-conscious approach to sensing.

Together, these collaborations demonstrate Seyond’s expanding role in connecting advanced sensing with AI, computing, and operational software. As investment in intelligent infrastructure grows, Seyond remains focused on bringing practical spatial intelligence solutions to cities, critical infrastructure and safe spaces.

About Seyond

Seyond is a global provider of high-performance LiDAR solutions for automotive, robotics, intelligent transportation, smart infrastructure, and other applications. Its comprehensive portfolio of advanced 3D sensing technologies enables accurate, reliable spatial intelligence across a wide range of environments.

For more information, visit www.seyond.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c501796e-599d-478e-86ec-4c3044e91d56

CONTACT: Seyond Media contact:

pr@seyond.com

VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) — North Sky Metals Corp. (TSXV:NSKY) (“North Sky” or the “Company“) is pleased to report the completion of its 2026 diamond drill program at the Natlan Project (“Natlan” or the “Project“), located approximately 24 km northeast of New Hazelton in west-central British Columbia (Figure 1). The Company completed 12 diamond drill holes totalling 4,372 metres to test two targets: the Ace porphyry copper-molybdenum target with associated gold and silver, which had not been previously drill tested, and the West gold target.

The 2026 program marks an important step for North Sky as Natlan advances from surface exploration to drilling. Three years of systematic mapping, sampling and geophysics have established three drill-ready targets across the 100 km² property. The first two targets have now been tested, and the third, the East copper-molybdenum-gold-silver porphyry target, is fully permitted for its first drill test planned in 2027.

Highlights

• Drilling program completed: 12 diamond drill holes totalling 4,372 metres were completed using a single helicopter-supported core rig;
• First-ever drilling at Ace: six holes totalling 2,507 metres tested the approximately 1.75 km by 0.9 km copper-molybdenum soil geochemical anomaly. The anomaly at Ace has associated silver and gold values, coincident induced polarization (“IP”) chargeability highs, a ring-shaped magnetic high and mapped potassic and phyllic alteration;
• Drilling at West: six holes totalling 1,865 metres followed up on limited historical drilling and tested approximately 350 metres of the approximately 900-metre-long by 550-metre-wide gold-arsenic soil anomaly with coincident chargeability and resistivity anomalies;
• East target ready for drilling: the undrilled East target is an approximately 2.5 km long copper-molybdenum-gold-silver trend with an associated tungsten geochemical anomaly along the eastern margin of the Natlan stock, plus coincident IP chargeability and resistivity anomalies. The East target is permitted for a first drill test planned for summer 2027;
• Drill core samples at the laboratory: 2,286 half-core samples and 384 samples for quality assurance/quality control (QA/QC) have been delivered to ALS for gold fire assay and multi-element analysis; and
• Fully permitted for further exploration: multi-year area-based (MYAB) permits cover follow-up drilling at Natlan to March 2031 and at Ace to March 2030.

“Completion of drilling at Natlan is a milestone for North Sky following three years of mapping, sampling and geophysics that went into development of the drill targets at Ace and West,” said Scott Ansell, President and CEO of North Sky. “With multi-year exploration permits in place across the Project, we can move directly from results to follow-up drilling, and planning for 2027 is already underway.”

“The assay results will help us assess the mineralization encountered and prioritize opportunities for follow-up drilling. While assays are pending, we are integrating geological logging and geophysical data into 3D models of both targets, to provide a basis for a focused 2027 drill program,” commented Arron Albano, Exploration Manager of North Sky.

Figure 1. Location of the Natlan Project, west-central British Columbia.

2026 Drill Program

Drilling was carried out by Driftwood Diamond Drilling and started at the lower-elevation West target before moving to the higher-elevation Ace target (Figures 2 and 4). North Sky developed the program based on the 2024 airborne magnetic survey and approximately 24 line-km of IP surveying completed in 2023 and 2025, together with soil and rock geochemistry and geological mapping. Drill hole details are provided in Table 1.

Table 1. 2026 Natlan diamond drill hole details (UTM NAD83 Zone 9N)

Hole ID	Target	Easting	Northing	Elev. (m)	Azimuth (°)	Dip (°)	Length (m)
NAT26DD001	West	603854	6142741	978	290	-50	304
NAT26DD002	West	603919	6142828	999	290	-50	324
NAT26DD003	West	603919	6142828	999	290	-65	335
NAT26DD004	West	603636	6142866	923	110	-50	373
NAT26DD005	West	603926	6142994	975	290	-50	307
NAT26DD006	West	603779	6142645	972	290	-50	222
NAT26DD007	Ace	606728	6139086	1690	295	-60	507
NAT26DD008	Ace	607160	6139027	1517	295	-60	452
NAT26DD009	Ace	607284	6139285	1373	295	-60	396
NAT26DD010	Ace	606925	6139226	1557	295	-75	402
NAT26DD011	Ace	606940	6139002	1637	295	-65	408
NAT26DD012	Ace	606728	6139086	1690	290	-85	342
Total	12 holes						4,372

Figure 2. Natlan Project (A) copper and (B) molybdenum soil geochemistry, with target areas and 2026 drilling.

Ace Target

The Ace target is a calc-alkaline porphyry copper-molybdenum target with associated gold and silver, defined by a prominent gossan over a northeast-trending swarm of Bulkley-age granitic dykes and a related granitic plug, with mapped potassic and phyllic alteration, chalcopyrite and molybdenite mineralization in a quartz stockwork, and an approximately 1.75 km by 0.9 km copper-molybdenum soil anomaly. High-grade grab samples of mineralized quartz veins and altered rocks have returned up to 2.12% copper and 0.83% molybdenum, and polymetallic veins cutting the intrusive rocks have returned up to 13.3 g/t gold and 1,800 g/t silver. Strong IP chargeability highs coincide with the stockwork and alteration zones, and airborne magnetics show a ring-shaped magnetic high over the dykes flanked by magnetic lows that follow the mapped alteration. Six holes were drilled from five pads across an area of approximately 550 m by 300 m, mostly oriented to the northwest across the dyke swarm, including two holes from a single pad to test the target at depth (Figure 3).

Figure 3. Ace target plan map showing 2026 drill holes, with copper and molybdenum soil contours, copper-in-rock samples, IP chargeability greater than 30 mV/V and magnetic features.

Figure 4. Natlan Project gold soil geochemistry, with target areas and 2026 drilling.

West Target

The West target is an approximately 900 m long by 550 m wide gold-arsenic soil geochemical anomaly, set within a broader north-northeast-trending arsenic anomaly, in an area largely covered by overburden and mature trees. Historical drilling in 2005 tested the target with two holes from a single pad.

In 2022, four of fourteen grab samples of quartz-arsenopyrite veins and altered feldspar porphyry float collected along an old logging road returned gold grades of 10.7, 5.26, 3.38 and 2.95 g/t, and follow-up sampling of similar quartz-arsenopyrite vein float in 2024 and 2025 returned up to 1.72 g/t gold.

IP surveys conducted by North Sky outlined chargeability highs and resistivity lows over the West target soil anomaly, which are strongest upslope to the east of the 2005 drilling. Airborne magnetics show a north-trending magnetic low that may mark a controlling structure. Six holes from five pads were drilled upslope and along strike from the 2005 pad, testing approximately 350 m of the anomaly (Figure 5).

Figure 5. West target plan map showing 2026 and 2005 drill holes, gold-in-soil and contoured arsenic-in-soil geochemistry.

East Target (Undrilled)

The East target is an approximately 2.5 km long copper-molybdenum-gold-silver trend along the eastern margin of the Natlan stock, where a gossan with phyllic and potassic alteration follows the contact with hornfelsed sedimentary rocks. A 500 m by 750 m core of chalcopyrite-molybdenite-pyrite quartz stockwork lies within a 700 m by 1,500 m copper-molybdenum-gold-silver talus fines anomaly, and high-grade grab samples have returned up to 3.0% copper, 1.25% molybdenum, 21.9 g/t gold and 224 g/t silver. A tungsten geochemical anomaly further sets the East target apart: 33 of approximately 64 rock samples from the target and its southeastern extension contain more than 0.01% W (100 ppm), up to 0.134% W (1,340 ppm), and tungsten in talus fines reaches up to 0.052% W (520 ppm).

The strongest resistivity anomaly and a strong chargeability anomaly over the East target coincide with the best exposed mineralization and the geophysical anomalies are interpreted to extend to more than 300 m depth, while a strong magnetic low flanks the eastern margin of the stock, where the contact corresponds to the strongest geochemistry over an approximately 2 km trend. The Company plans to complete the first drill test of the East target in summer 2027 and permits for drilling are already in place.

Next Steps

The 2026 program of drilling, core logging and sampling is complete. Assay results will be reported in upcoming news releases. Results will be integrated with geological logging and the geophysical and surface geochemical datasets to prioritize follow-up drilling at Ace and West.

North Sky has also completed a helicopter-borne MobileMT electromagnetic and magnetic survey over the entire Natlan Project, flown by Expert Geophysics Surveys Inc., on east-west lines spaced 200 m apart. Interpretation of the final survey data is underway, and the results will be reported at a later date.

Exploration Permitting

North Sky holds multi-year area-based (MYAB) Mines Act permits covering the Project, one for the Natlan claims (valid to March 2031) and one for the Ace claims (valid to March 2030), which together authorize up to 100 helicopter-supported drill sites and 115 line-km of IP surveys across the Ace, West and East targets.

First Nations

The Natlan Project lies within the traditional territory of the Gitxsan Nation, on the lax yip (territories) of the Hereditary Chiefs Luutkudziiwus and Yagosip. North Sky’s engagement with the Chiefs is ongoing and hands-on. It includes regular meetings, information sharing and updates on the Company’s activities, as well as helicopter visits to the Project so the Chiefs can see the work firsthand and return to areas of their territories where their families have lived, harvested and kept their adaawk (oral histories) for generations. The Chiefs are compensated for their time, which supports the feast system that underpins Gitxsan governance and benefits the wider Gitxsan community.

These visits also give the Company a direct view of the Chiefs’ priorities for the land. Foremost among them are water and fish habitat.

North Sky regards consultation as a long-term relationship and not a one-time permitting step, and incorporates the Chiefs’ knowledge of the land into how and where it works. The 2026 program was also supported by local and regional businesses, including Raven 37 for field labour and Skookum Daxgyet Services for drill pad construction.

QA/QC and Sampling Protocol

All drill core was logged, photographed and sampled on site by Company personnel. Sample intervals were generally 1 to 2 metres at the West target and 3 metres at the Ace target. Core was cut in half with a diamond saw, with one half sent for analysis and the other retained for reference. A total of 2,286 core samples representing 4,165 metres of core were submitted, together with 384 QA/QC samples comprising certified reference materials, blanks, and field duplicates.

Company personnel delivered samples to the ALS Canada Ltd. preparation facility in Terrace, British Columbia, where samples are crushed to 70% passing 2 mm and a 250 g split is pulverized to 85% passing 75 microns. Pulps are analyzed at ALS in North Vancouver for gold by 30 g fire assay with an ICP-AES finish (Au-ICP21), and by multi-element analysis (48 elements) using a four-acid digestion with an ICP-MS finish (ME-MS61). Over-limit copper and other elements are re-analyzed by four-acid ore-grade methods (Cu-OG62, ME-OG62). ALS is independent of the Company.

About the Natlan Project

The 10,065 hectare Natlan Project consists of 14 contiguous mineral tenures in the Omineca Mining Division, approximately 24 km northeast of New Hazelton and within 23 km of the provincial power grid and 18 km of the CN rail line. North Sky owns 100% of the Ace claims and holds an option to earn a 100% interest in the Natlan claims. The Project lies near the southeastern margin of the Bowser Basin, close to the Skeena Arch, and is underlain by Bowser Lake Group sedimentary rocks intruded by the Late Cretaceous Natlan stock and related dyke swarms of the Bulkley plutonic suite, which is associated with porphyry deposits in the region, including the past-producing Huckleberry mine. The Qualified Person has not verified the information regarding the Huckleberry mine or other regional deposits, and mineralization at those deposits is not necessarily indicative of mineralization on the Natlan Project.

The Project has been explored intermittently since 1967. More than 3,500 soil samples, including B- and C-horizon soils, talus fines and Ah (humus) soils, and more than 800 rock samples have been collected across the Project, including 1,675 soil and 298 rock samples collected by North Sky in 2023 and 2024. North Sky has also completed a 360 line-km airborne magnetic survey and approximately 24 line-km of IP surveying. Further information on the Project is available in the NI 43-101 technical report titled “NI 43-101 Technical Report on the Natlan Project in west-central British Columbia, Canada” by Jean Pautler, P.Geo., with an effective date of June 30, 2026, available on the Company’s profile on SEDAR+ (www.sedarplus.ca) and on the Company’s website at www.northskymetals.com.

Qualified Person

The scientific and technical information contained in this news release has been reviewed and approved by Arron Albano, B.Sc., P.Geo., Exploration Manager for North Sky Metals Corp., who is a Qualified Person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Mr. Albano has verified the data disclosed in this news release, including sampling and analytical data, by reviewing the Company’s databases, analytical certificates and the technical report.

ABOUT NORTH SKY METALS CORP.

North Sky Metals Corp. is a Canadian mineral exploration company focused on copper and gold projects in Canada. The Company’s flagship 100 km² Natlan Project in west-central British Columbia, comprising the 100%-owned Ace claims and the Natlan claims under option to earn a 100% interest, hosts the Ace and East copper porphyry targets and the West gold target, all fully permitted for drilling. The Company also holds the 110 km² Jet copper project in Nunavut. North Sky is focused on advancing these and other projects through disciplined, discovery-driven exploration.

ON BEHALF OF THE BOARD OF DIRECTORS OF NORTH SKY METALS CORP.

Scott Ansell,
President, CEO & Director

FOR FURTHER INFORMATION, PLEASE CONTACT:

Scott Ansell
(T): +1 (604) 536-2711
(E): info@northskymetals.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Information

Certain information and statements in this news release may be considered forward-looking information or forward-looking statements for purposes of applicable securities laws (collectively, “forward-looking statements”). Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative and grammatical variations) of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved. Forward-looking statements in this news release include, without limitation, statements relating to the timing of receipt and release of assay results from the 2026 drill program; the interpretation of drilling, geological, geochemical and geophysical results, including the 3D modelling of the Ace and West targets; the interpretation and reporting of the results of the MobileMT electromagnetic and magnetic survey; the Company’s plans for follow-up drilling at the Ace and West targets, including a 2027 drill program, and a first drill test of the East target in summer 2027; the use and continued validity of the Company’s multi-year area-based permits; the Company’s ability to earn a 100% interest in the Natlan claims under its option agreement; the Company’s ongoing engagement with the Gitxsan Hereditary Chiefs; and the Company’s stated plans and schedules for the Natlan Project.

Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the Company’s actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management’s current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. Material expectations, estimates and assumptions pertaining to forward-looking statements include, but are not limited to: the receipt of assay results within expected timeframes; the reliability of the Company’s sampling, QA/QC and analytical procedures; the accuracy of geological, geochemical and geophysical interpretations; the continued validity of, and the Company’s compliance with, its permits; the Company’s ability to make the payments and incur the expenditures required to exercise its option on the Natlan claims; the availability of drilling contractors, helicopter support, equipment and personnel on reasonable terms; favourable weather and access conditions; continued constructive relationships with the Gitxsan Hereditary Chiefs and local communities; the strength of precious and base metals prices; and the availability of additional capital on acceptable terms to fund the Company’s planned exploration. A number of risks and uncertainties could cause actual results to differ materially from those expressed or implied by the forward-looking statements, including, but not limited to: delays in receiving or interpreting assay results; assay results that do not meet expectations or do not confirm the presence of economic mineralization; the uncertainty of geophysical and geochemical interpretations; delays or cost overruns in exploration programs; weather, access and seasonal constraints; unavailability of contractors, helicopters or equipment; failure to satisfy the terms of the option agreement for the Natlan claims; changes in permitting requirements or the suspension, cancellation or non-renewal of permits; Indigenous rights and title claims and the outcome of consultation; global economic conditions; precious and base metal price fluctuations; government regulation and policy risks; public involvement in the permitting process; environmental regulatory requirements and risks; the market price of the Company’s shares; the Company’s additional capital requirements and the availability of financing; competition for properties and experienced employees; possible loss of interests in exploration and development properties; inherent danger in mining and mineral exploration; the nature of exploration and development projects; political risk; currency fluctuations; the Company has no history of mining operations; property title rights; dependence on key personnel and qualified and experienced employees; insurance coverage; dilution from further equity financing and outstanding stock options and share purchase warrants; litigation and other legal proceedings; and conflicts of interest.

Undue reliance should not be placed on forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are in many cases beyond the Company’s control. Forward-looking statements are not guarantees of future performance, and the Company’s actual results may differ materially from statements made in this news release. The forward-looking statements in this news release are made as of the date hereof, and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/4b07422c-ceb4-4a94-ba22-bc873e4b59a8

https://www.globenewswire.com/NewsRoom/AttachmentNg/e388e6b0-73d7-4c8a-ae5d-2a1d3d14102b

https://www.globenewswire.com/NewsRoom/AttachmentNg/17ee2572-6706-45b4-b48e-0958334bfcbc

https://www.globenewswire.com/NewsRoom/AttachmentNg/ab972e24-20ed-495c-bbdd-e246ccdcdf90

https://www.globenewswire.com/NewsRoom/AttachmentNg/348b2db5-a3df-4c94-a1f4-678dbdc55f00

Seasoned biopharmaceutical executive with more than 30 years of leadership experience spanning clinical development, regulatory strategy and operational execution appointed to lead company into new phase of clinical development and growth

NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (Nasdaq: AVXL) (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for central nervous system diseases with significant unmet medical needs, today announced that on November 1, 2026, its Board of Directors appointed Terrie Kellmeyer, Ph.D., who had been serving as the Company’s Interim Chief Executive Officer, as the Company’s President and Chief Executive Officer. She will also join Anavex’s Board of Directors.

“Dr. Kellmeyer has provided steady leadership and a clear vision during an important period for Anavex, sharpening the focus of our clinical programs and advancing our engagement with the FDA,” said Peter Donhauser, D.O., member of the Board of Directors. “She brings a deep understanding of our science, a disciplined approach to execution and an unwavering commitment to patients. The Board’s decision reflects our unequivocal support for her strategy and her plans to build a top-notch management team, and we are confident she is the ideal leader to drive Anavex to its full potential.”

“I am honored by the Board’s confidence and grateful to our team, whose dedication over the past several months has positioned Anavex for its next chapter,” said Dr. Kellmeyer. “We have strengthened our operations, advanced each of our programs and established a constructive dialogue with the FDA. My priorities are clear: disciplined execution of our clinical plans, generating high-quality data to support regulatory decisions and transparent communication with patients, investors and regulators. We are accountable to the patients and families we serve and to our shareholders, and we intend to deliver on our commitments.”

Anavex is developing blarcamesine (ANAVEX^®2-73) in Alzheimer’s disease, Rett syndrome and Fragile X syndrome. Under Dr. Kellmeyer’s interim leadership, the Company has achieved and recently announced several key milestones across its development portfolio, including the completion of key clinical pharmacology studies, U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application in Fragile X syndrome, and continued progress supporting its planned Phase 3 Rett syndrome program. Anavex’s strategy is centered on close collaboration with the FDA and advancing blarcamesine through well-designed clinical studies. With active INDs across each of its core indications, Anavex remains focused on generating clinical evidence, advancing its precision medicine approach and pursuing potential new treatment options for patients and families.

Dr. Kellmeyer brings more than 30 years of biopharmaceutical industry experience spanning clinical development, regulatory affairs, clinical operations and medical affairs. Prior to her appointment as Chief Executive Officer, she served as Interim Chief Executive Officer and Senior Vice President, Clinical Development at Anavex. Before joining Anavex, Dr. Kellmeyer held senior leadership positions at Aardvark Therapeutics, Acer Therapeutics, Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Amylin Pharmaceuticals and Gen-Probe, and played a key role in the advancement of multiple development programs and the achievement of significant regulatory milestones in the United States and Europe. Dr. Kellmeyer received her Ph.D. in Molecular Biology from SUNY Syracuse and completed a postdoctoral fellowship at the University of Rochester.

About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical-stage biopharmaceutical company developing innovative therapeutics for the treatment of central nervous system diseases with high unmet medical need. Further information is available at www.anavex.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding the Company’s clinical trial plans, preclinical and clinical data, clinical development programs and business prospects, the Company’s leadership strategy and management team development, the execution and advancement of its clinical development plans, its planned Phase 3 Rett syndrome program, its collaboration and interactions with the FDA, the advancement of blarcamesine, the generation of additional clinical evidence, and the pursuit of potential new treatment options are forward-looking statements. These statements can be identified by the use of forward-looking terminology, including the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could” and similar expressions, or the negative thereof. Many factors may cause actual results to differ materially from those projected in any of such forward-looking statements, including volatility in the Company’s stock price and the market in general; the Company’s ability to raise additional capital; challenges seeking, and ultimately obtaining, regulatory approval for the Company’s product candidates; the ability of Fast Track designation or Breakthrough Therapy designation to lead to a faster FDA review and approval process; the Company’s ability to maintain any benefits associated with Orphan Drug Designation, including market exclusivity; undesirable side effects caused by the Company’s product candidates; the Company’s ability to attract and retain highly qualified personnel; the Company’s reliance on third parties; the Company’s ability to obtain and maintain sufficient intellectual property protection for our product candidates; the Company’s ability to defend against claims of intellectual property infringement; the Company’s ability to compete in the highly competitive biotechnology and pharmaceutical industries; and the other risks and uncertainties set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, filed with the Securities and Exchange Commission (“SEC”) on November 25, 2025, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2025, filed with the SEC on February 9, 2026, the Company’s Form 10-K/A for the fiscal year ended September 30, 2025, filed with the SEC on August 28, 2026, the Company’s Form 10-Q/A for the quarterly period ended December 31, 2025, filed with the SEC on August 28, 2026, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the SEC on August 28, 2026, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 28, 2026, and subsequent filings and furnishings with the SEC, which should be considered together with any forward-looking statement. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof except as required by law.

Investor Relations:

SCR Partners, LLC
Alex Arzeno
Tel: 203-550-3972
Email: alex@scr-ir.com

Tripp Sullivan
Tel: 615-942-7077
Email: tsullivan@scr-ir.com

Media:

Sam Brown, LLC
Christy Curran
Tel: 615-414-8668
Email: christycurran@sambrown.com

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1×1 investor meetings at the UBS Global Biopharma Conference on November 16-17, 2026.

Details of the presentation can be found below.

Format: Fireside Chat
Presenter: Mani Mohindru, PhD (President and CEO)
Date: November 16, 2026
Time: 2:40 PM GMT

Interested parties can register for and access the live webcast for the conference by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Cardiff’s lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated mCRC, addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single-agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.

For more information, please visit https://www.cardiffoncology.com.

Investor Contact: 
Candice Masse 
Astr Partners 
candice.masse@astrpartners.com 

Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com

ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) — Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences:

Canaccord Genuity 20^th Annual MedTech, Diagnostics, Digital Health & Services Forum 
Participation: Fireside Chat and 1×1 investor meetings
Date/Time: Fireside Chat Wednesday, November 11, 2026, 10:00 AM ET

Jefferies Global Healthcare Conference in London
Participation: Fireside Chat and 1×1 investor meetings
Date/Time: Fireside Chat Tuesday, November 17, 2026, 8:30 AM ET

Piper Sandler 38^th Annual Healthcare Conference
Participation: Presentation and 1×1 investor meetings
Date/Time: Presentation Wednesday, December 2, 2026, 8:00 AM ET

Webcast events can be accessed live through the Investors page at www.axogeninc.com. For those unable to listen to the live broadcast, the replay will be archived for 90 days and available on the Investors page at www.axogeninc.com.

About Axogen

Axogen (Nasdaq: AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network.

Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, Avive+ Soft Tissue Matrix™, and NerveTape®.

Contact:
Axogen, Inc.
InvestorRelations@axogeninc.com